UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2691-2697

2012

Volltextzugriff (PDF)

Ipilimumab in patients with cancer and the management of dermatologic adverse events

Journal of the American Academy of Dermatology, 2014-07, Vol.71 (1), p.161-169

2014

Volltextzugriff (PDF)

Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease

Journal of immunotherapy (1997), 2016-05, Vol.39 (4), p.188-190

2016

Volltextzugriff (PDF)

Interactions from complementary and alternative medicine in patients with melanoma

Melanoma research, 2017-06, Vol.27 (3), p.238-242

2017

Volltextzugriff (PDF)

Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

Journal of patient-reported outcomes, 2021-08, Vol.5 (1), p.78-78, Article 78

2021

Volltextzugriff (PDF)

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Journal of cancer research and clinical oncology, 2024-10, Vol.150 (10), p.454, Article 454

2024

Volltextzugriff (PDF)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Frontiers in oncology, 2021-05, Vol.11, p.672172-672172

2021

Volltextzugriff (PDF)

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Cancer treatment reviews, 2016-04, Vol.45, p.7-18

2016

Volltextzugriff (PDF)

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

European journal of cancer (1990), 2022-11, Vol.176, p.88-99

2022

Volltextzugriff (PDF)

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Cancer Immunology, Immunotherapy, 2018-05, Vol.67 (5), p.825-834

2018

Volltextzugriff (PDF)

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

European journal of cancer (1990), 2021-02, Vol.144, p.382-385

2021

Volltextzugriff (PDF)

Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade

European journal of cancer (1990), 2024-03, Vol.200, p.113536-113536, Article 113536

2024

Volltextzugriff (PDF)

Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?

European journal of cancer (1990), 2020-10, Vol.138, p.169-171

2020

Volltextzugriff (PDF)

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

European journal of cancer (1990), 2021-05, Vol.149, p.1-10

2021

Volltextzugriff (PDF)

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Cancer Immunology, Immunotherapy, 2016-08, Vol.65 (8), p.951-959

2016

Volltextzugriff (PDF)

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency

JAMA dermatology (Chicago, Ill.), 2016-12, Vol.152 (12), p.1387

2016

Volltextzugriff (PDF)

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Journal of cancer research and clinical oncology, 2024-05, Vol.150 (5), p.252, Article 252

2024

Volltextzugriff (PDF)

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

European journal of cancer (1990), 2021-05, Vol.148, p.61-75

2021

Volltextzugriff (PDF)

The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

European journal of cancer (1990), 2024-03, Vol.199, p.113505-113505, Article 113505

2024

Volltextzugriff (PDF)

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

Melanoma research, 2024-02, Vol.34 (1), p.44-53

2024

Volltextzugriff (PDF)

Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma

Melanoma research, 2019-04, Vol.29 (2), p.187-195

2019

Volltextzugriff (PDF)

Rare cutaneous side effect of vemurafenib : Fever and exanthema 14 days after therapy initiation

Hautarzt, 2021-11, Vol.72 (11), p.1014-1016

2021

Volltextzugriff (PDF)

67-year-old male with cervical lymph node swelling : Preparation for the specialist examination: part 45

Hautarzt, 2019-04, Vol.70 (Suppl 1), p.72-74

Kähler, Katharina C

2019

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Full Collection 2018

ThemaPatients

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(43)

Sprache

Englisch
(41)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Oncology
(32)
Humans
(26)
Melanoma
(22)
Melanoma - Drug Therapy
(16)
Male
(14)
Aged
(13)
Skin Neoplasms - Drug Therapy
(13)
Female
(12)
Dermatology
(10)
Middle Aged
(10)
Melanoma - Pathology
(9)
Adult
(8)
Skin Neoplasms - Pathology
(8)
Immune Checkpoint Inhibitors
(7)
Ipilimumab
(7)
Skin Cancer
(7)
Treatment Outcome
(7)
Antineoplastic Agents - Therapeutic Use
(6)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Ipilimumab in patients with cancer and the management of dermatologic adverse events

Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease

Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events

Interactions from complementary and alternative medicine in patients with melanoma

Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade

Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma

Rare cutaneous side effect of vemurafenib : Fever and exanthema 14 days after therapy initiation

67-year-old male with cervical lymph node swelling : Preparation for the specialist examination: part 45

Aktive Filter

Suchergebnisse filtern